The National Advisory Committee on Immunization (NACI) has released new guidelines for vaccinations against COVID-19 for Fall of 2024. We’ve highlighted some of the recommendations for immunocompromised individuals as well as the general population.
Read the full advisory: Guidance on the use of COVID-19 vaccines during the fall of 2024 – Canada.ca
Immunocompromised Individuals
6months – 5 years
- additional dose recommended (3 of Moderna Spikevax preferred, or 4 of Pfizer-BioNTech Comirnaty)
- 4-8 weeks between doses
Age 5+
- 2 doses strongly recommended
- 4-8 weeks between doses
- additional dose advised
- although two doses can provide good protection, not all individuals with immunocompromising conditions will respond to vaccination in the same way and not all will have a previous SARS-CoV-2 infection in order to benefit from the immunological advantage of hybrid immunity. In some cases, an additional dose may be needed to develop adequate protection, while some others will not be able to mount a sufficient response even with additional doses. Healthcare providers can use clinical discretion to determine the potential benefit of a third dose.
General Population
Vaccination is strongly recommended for:
- Adults 65+
- Individuals 6 months+ who
- Reside in group living settings
- Have underlying medical conditions that place them at higher risk of severe COVID-19
- Are pregnant
- Provide essential community services
- Are Indigenous and/or racialized
Vaccination is advised for:
- All other previously vaccinated and unvaccinated individuals (6 months+) who are not at increased risk for SARS-CoV-2 infection or severe COVID-19 disease (i.e., not on the list above)
Read the full advisory: Guidance on the use of COVID-19 vaccines during the fall of 2024 – Canada.ca